These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38385175)

  • 1. In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy.
    Williams MJ; Halabi CM; Patel HM; Joseph Z; McCommis K; Weinheimer C; Kovacs A; Lima F; Finck B; Malluche H; Hruska KA
    Am J Physiol Renal Physiol; 2024 May; 326(5):F751-F767. PubMed ID: 38385175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
    Hruska KA; Sugatani T; Agapova O; Fang Y
    Bone; 2017 Jul; 100():80-86. PubMed ID: 28119179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.
    Touchberry CD; Green TM; Tchikrizov V; Mannix JE; Mao TF; Carney BW; Girgis M; Vincent RJ; Wetmore LA; Dawn B; Bonewald LF; Stubbs JR; Wacker MJ
    Am J Physiol Endocrinol Metab; 2013 Apr; 304(8):E863-73. PubMed ID: 23443925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
    Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
    Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner.
    Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
    Fang Y; Ginsberg C; Seifert M; Agapova O; Sugatani T; Register TC; Freedman BI; Monier-Faugere MC; Malluche H; Hruska KA
    J Am Soc Nephrol; 2014 Aug; 25(8):1760-73. PubMed ID: 24578135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
    Zhang S; Gillihan R; He N; Fields T; Liu S; Green T; Stubbs JR
    Kidney Int; 2013 Oct; 84(4):713-21. PubMed ID: 23698235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF23 impairs peripheral microvascular function in renal failure.
    Verkaik M; Juni RP; van Loon EPM; van Poelgeest EM; Kwekkeboom RFJ; Gam Z; Richards WG; Ter Wee PM; Hoenderop JG; Eringa EC; Vervloet MG;
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1414-H1424. PubMed ID: 30028196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.
    Hu MC; Shi M; Cho HJ; Adams-Huet B; Paek J; Hill K; Shelton J; Amaral AP; Faul C; Taniguchi M; Wolf M; Brand M; Takahashi M; Kuro-O M; Hill JA; Moe OW
    J Am Soc Nephrol; 2015 Jun; 26(6):1290-302. PubMed ID: 25326585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats.
    Nordholm A; Egstrand S; Gravesen E; Mace ML; Morevati M; Olgaard K; Lewin E
    Pflugers Arch; 2019 Aug; 471(8):1079-1094. PubMed ID: 31236663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
    Grabner A; Faul C
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological presentation of cardiac mitochondria in a rat model for chronic kidney disease.
    Bigelman E; Cohen L; Aharon-Hananel G; Levy R; Rozenbaum Z; Saada A; Keren G; Entin-Meer M
    PLoS One; 2018; 13(6):e0198196. PubMed ID: 29889834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis.
    Mace ML; Olgaard K; Lewin E
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between GFR, intact PTH, oxidized PTH, non-oxidized PTH as well as FGF23 in patients with CKD.
    Zeng S; Querfeld U; Feger M; Haffner D; Hasan AA; Chu C; Slowinski T; Bernd Dschietzig T; Schäfer F; Xiong Y; Zhang B; Rausch S; Horvathova K; Lang F; Karl Krämer B; Föller M; Hocher B
    FASEB J; 2020 Nov; 34(11):15269-15281. PubMed ID: 32964520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.